Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

References

• Babalonis S, Raup-Konsavage WM, Akpunonu PD, Balla A, Vrana KE. Δ8-THC: legal status, widespread availability, and safety concerns. Cannabis Cannabinoid Res. 2021;6(5):362–365. doi:10.1089/can.2021.0097
   PubMedGoogle Scholar
• Hollister LE, Gillespie HK. Delta‐8‐ and delta‐9‐tetrahydrocannabinol; Comparison in man by oral and intravenous administration. Clin Pharmacol Ther. 1973;14(3):353–357. doi:10.1002/cpt1973143353
   PubMed Web of Science ®Google Scholar
• Leas EC. The hemp loophole: a need to clarify the legality of delta-8-THC and other hemp-derived tetrahydrocannabinol compounds. Am J Public Health. 2021;111(11):1927–1931. doi:10.2105/ajph.2021.306499
   PubMed Web of Science ®Google Scholar
• Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10:697. doi:10.3389/fpls.2019.00697
   PubMed Web of Science ®Google Scholar
• Johnson L. CBD oracle lab study shows some delta-8 products are 7700% over the legal delta-9 THC limit. ORACLE. Available from: https://cbdoracle.com/news/delta-8-thc-products-market-study-consumer-safety-and-legality/#The-labeling-lies. Accessed January 18, 2023.
   Google Scholar
• Gong H, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clin Pharmacol Ther. 1984;35(1):26–32. doi:10.1038/clpt.1984.4
   PubMed Web of Science ®Google Scholar
• Abrahamov A, Mechoulam R, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56(23–24):2097–2102. doi:10.1016/0024-3205(95)00194-B
   PubMed Web of Science ®Google Scholar
• Marcu J. The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report. Dialogues Clin Neurosci. 2020;22(3):289–293. doi:10.31887/dcns.2020.22.3/jmarcu
   PubMed Web of Science ®Google Scholar
• Sheet D fact. What is K2? What is its origin? getsmartaboutdrugs. Available from: https://www.dea.gov/sites/default/files/2020-06/K2-spice-2020.pdf. Accessed January 18, 2023.
   Google Scholar
• Kiley B. “Synthetic Marijuana” has nothing to do with actual marijuana; 2015. Available from: https://www.thestranger.com/blogs/2015/09/16/22867088/synthetic-marijuana-has-nothing-to-do-with-actual-marijuana. Accessed January 18, 2023.
   Google Scholar
• Goldstein C. “Synthetic pot” it’s not. Bans bring unintended consequences; 2013. Available from: https://www.inquirer.com/philly/columnists/philly420/Synthetic_pot_its_not_Designer_drug_ban_brings_unintended_consequences_.html&outputType=app-web-view. Accessed January 18, 2023.
   Google Scholar
• Knopf A. CDC and FDA warn of delta‐8 THC harms. Alcohol Drug Abus Wkly. 2021;33(36):7. doi:10.1002/adaw.33199
   Google Scholar
• FDA. 5 things to know about delta-8 tetrahydrocannabinol – delta-8 THC. Available from: https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. Accessed January 18, 2023.
   Google Scholar
• Xu R, Wang Q. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection. BMC Bioinform. 2014;15(1):17. doi:10.1186/1471-2105-15-17
   PubMedGoogle Scholar
• Medical Dictionary for Regulatory Activities (MedDRA) version 24.1. Available from: https://www.meddra.org/index.asp. Accessed January 22, 2023.
   Google Scholar
• Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidem Dr S. 2001;10(5):407–410. doi:10.1002/pds.615
   PubMed Web of Science ®Google Scholar
• FDA. Questions and answers on FDA’s Adverse Event Reporting System (FAERS). Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed January 18, 2023.
   Google Scholar
• Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–1369. doi:10.1001/archinte.165.12.1363
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Furberg CD. serious adverse drug events reported to the food and drug administration, 1998–2005. Arch Intern Med. 2007;167(16):1752–1759. doi:10.1001/archinte.167.16.1752
   PubMed Web of Science ®Google Scholar
• Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011;171(6):591–593. doi:10.1001/archinternmed.2011.89
   PubMedGoogle Scholar
• Zink RC, Huang Q, Zhang LY, Bao WJ. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Chin J Nat Med. 2013;11(3):314–320. doi:10.1016/s1875-5364(13)60035-7
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidem Dr S. 2004;13(8):519–523. doi:10.1002/pds.1001
   PubMed Web of Science ®Google Scholar
• Green EJPH and S, Green JPH and S, Green S. Cochrane handbook for systematic reviews of interventions V5.1.0 2011; 2011. Available from: https://handbook-5-1.cochrane.org/chapter_16/16_9_2_studies_with_zero_cell_counts.htm. Accessed January 4, 2022.
   Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi:10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Montastruc J, Sommet A, Bagheri H, Lapeyre‐Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Brit J Clin Pharmaco. 2011;72(6):905–908. doi:10.1111/j.1365-2125.2011.04037.x
   PubMed Web of Science ®Google Scholar
• Simon TA, Gomez A, Marcu J. What Cannabis related data is Reported in the FDA FAERS Database. Cannabis Res Conf. 2021. doi:10.26226/morressier.60dc99f4e537565438d6c0b4
   Google Scholar
• Akpunonu P, Baum RA, Reckers A, et al. Sedation and acute encephalopathy in a pediatric patient following ingestion of delta-8-tetrahydrocannabinol gummies. Am J Case Reports. 2021;22:e933488. doi:10.12659/ajcr.933488
   PubMed Web of Science ®Google Scholar
• Jo NY, Chu CC, Ramsey BC. Brugada electrocardiogram pattern induced by recreational delta-8-tetrahydrocannabinol (THC): a case report. Cureus. 2021;13(10):e19058. doi:10.7759/cureus.19058
   PubMed Web of Science ®Google Scholar
• Knopf A. Keep your eye on…The risks of delta-8 THC in CBD and hemp. Brown Univ Child Adolesc Behav Lett. 2021;37(11):2. doi:10.1002/cbl.30583
   Google Scholar
• Delta 8 PSA, Michigan poison center. Wayne State University. Available from: https://static1.squarespace.com/static/5f777ef4c9213f4b5800fc9a/t/60832a49de02a46cdbd3a25d/1619208777303/Delta-8+THC+PSA+final.pdf. Accessed December 30, 2021.
   Google Scholar
• Yoshimura H, Watanabe K, Oguri K, Fujiwara M, Ueki S. Synthesis and pharmacological activity of a phosphate ester of delta8-tetrahydrocannabinol. J Med Chem. 1978;21(10):1079–1081. doi:10.1021/jm00208a014
   PubMed Web of Science ®Google Scholar
• Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharm. 1973;25(3):363–372. doi:10.1016/0041-008x(73)90310-4
   PubMed Web of Science ®Google Scholar
• Sagratella S, Pézzola A, Scotti de Carolis A. An EEG investigation on nabilone, a synthetic cannabinoid, in rabbits. Pharmacol Res Commun. 1986;18(7):653–662. doi:10.1016/0031-6989(86)90107-4
   PubMedGoogle Scholar
• Wada JA, Osawa T, Corcoran ME. Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese Baboons, Papio papio. Epilepsia. 1975;16(3):439–448. doi:10.1111/j.1528-1157.1975.tb06071.x
   PubMed Web of Science ®Google Scholar
• Kruger DJ, Kruger JS. Consumer Experiences with Delta-8-THC: medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC. Cannabis Cannabinoid Res. 2021. doi:10.1089/can.2021.0124
   Google Scholar
• Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: a systematic review. J Pediatrics. 2017;190:142–152. doi:10.1016/j.jpeds.2017.07.005
   PubMed Web of Science ®Google Scholar
• Herdeiro MT, Polónia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions. Drug Safety. 2008;31(4):335–344. doi:10.2165/00002018-200831040-00007
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32:19–31. doi:10.2165/00002018-200932010-0000
   PubMed Web of Science ®Google Scholar
• Figueiras A, Herdeiro MT, Polónia J, et al. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006;296:1086–1093. doi:10.1001/jama.296.9.1086
   PubMed Web of Science ®Google Scholar
• Du D, Goldsmith J, Aikin KJ, Encinosa WE, Nardinelli C. Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still low. Health Affair. 2017;31(5):1022–1029. doi:10.1377/hlthaff.2010.1004
   Google Scholar
• World Health Organization. WHO Expert Committee on Drug Dependence. 2003:25.
   Google Scholar
• Meehan-Atrash J, Rahman I. Novel Δ8-tetrahydrocannabinol vaporizers contain unlabeled adulterants, unintended byproducts of chemical synthesis, and heavy metals. Chem Res Toxicol. 2021. doi:10.1021/acs.chemrestox.1c00388
   Web of Science ®Google Scholar